A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis

Trial Profile

A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Sponsors Galapagos NV
  • Most Recent Events

    • 03 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top